GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Recommendation of "Reduce" from Brokerages

Key Points

• GSK PLC Sponsored ADR has an average consensus rating of "Reduce" from seven brokerages, with one analyst recommending a sell and six recommending a hold.
• The company's recent earnings report exceeded analyst expectations, with a reported $1.23 EPS on revenue of $10.64 billion, up 1.3% from the same quarter last year.
• GSK also declared a quarterly dividend of $0.4206, leading to an annualized payout of $1.68 and a yield of 4.1%.

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) has earned an average rating of "Reduce" from the seven research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $37.3750.

Several research analysts recently issued reports on the stock. Berenberg Bank reissued a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th.

GSK Stock Down 0.2%

NYSE:GSK traded down $0.06 during trading hours on Friday, reaching $40.30. The company's stock had a trading volume of 2,019,480 shares, compared to its average volume of 3,617,412. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. GSK has a one year low of $31.72 and a one year high of $42.63. The business's 50-day moving average is $38.85 and its 200-day moving average is $38.53. The company has a market cap of $82.08 billion, a price-to-earnings ratio of 18.66, a price-to-earnings-growth ratio of 2.01 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The company had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities research analysts predict that GSK will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio is 77.78%.

Hedge Funds Weigh In On GSK

Hedge funds and other institutional investors have recently bought and sold shares of the business. Twin Peaks Wealth Advisors LLC bought a new position in GSK in the second quarter valued at approximately $25,000. HHM Wealth Advisors LLC boosted its stake in GSK by 222.2% in the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after acquiring an additional 460 shares during the last quarter. Costello Asset Management INC bought a new position in GSK in the first quarter valued at approximately $31,000. Richardson Financial Services Inc. boosted its stake in GSK by 127.9% in the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after acquiring an additional 472 shares during the last quarter. Finally, SOA Wealth Advisors LLC. boosted its stake in GSK by 252.1% in the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company's stock valued at $32,000 after acquiring an additional 605 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.